Doximity Stock Hits 12-Month Low After Analyst Downgrade

JPMorgan Chase & Co. lowers price target on the medical networking platform company

Feb. 23, 2026 at 8:03pm by Ben Kaplan

Shares of Doximity, Inc. (NASDAQ:DOCS) hit a new 52-week low after JPMorgan Chase & Co. downgraded the stock and lowered its price target. The investment bank cited concerns about the company's growth prospects in its latest research note.

Why it matters

Doximity is a leading digital platform for healthcare professionals, providing secure communication tools and clinical news updates. The company's stock performance is closely watched as an indicator of sentiment around the broader telehealth and digital health sectors.

The details

JPMorgan Chase & Co. lowered its price target on Doximity from $40 to $33 and maintained a 'neutral' rating on the stock. The investment bank noted slowing growth in the company's core networking and telehealth offerings. Several other analysts have also recently cut their price targets on Doximity, citing concerns about increased competition and macroeconomic headwinds impacting the digital health space.

  • Doximity's share price hit a new 52-week low during mid-day trading on Monday, February 23, 2026.

The players

Doximity, Inc.

A leading digital platform for healthcare professionals, providing secure communication tools and clinical news updates.

JPMorgan Chase & Co.

A major global investment bank that downgraded Doximity's stock and lowered its price target.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The downgrade and price target cut from JPMorgan Chase & Co. reflect broader concerns about growth and competition in the digital health space. Doximity's stock performance will continue to be closely watched as an indicator of sentiment around the telehealth and medical networking sectors.